KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Current Assets (2016 - 2026)

TherapeuticsMD filings provide 17 years of Current Assets readings, the most recent being $15.3 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 21.99% to $15.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.3 million, a 21.99% increase, with the full-year FY2025 number at $14.4 million, up 17.83% from a year prior.
  • Current Assets hit $15.3 million in Q1 2026 for TherapeuticsMD, up from $14.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $98.6 million in Q2 2022 to a low of $11.5 million in Q1 2024.
  • Median Current Assets over the past 5 years was $14.5 million (2025), compared with a mean of $30.4 million.
  • Biggest five-year swings in Current Assets: tumbled 80.11% in 2023 and later grew 21.99% in 2026.
  • TherapeuticsMD's Current Assets stood at $55.4 million in 2022, then crashed by 78.69% to $11.8 million in 2023, then rose by 3.93% to $12.3 million in 2024, then grew by 17.83% to $14.4 million in 2025, then rose by 5.66% to $15.3 million in 2026.
  • The last three reported values for Current Assets were $15.3 million (Q1 2026), $14.4 million (Q4 2025), and $14.5 million (Q3 2025) per Business Quant data.